Biotech

OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies

2021-06-30 09:29 1284

NEW YORK, June 29, 2021 /PRNewswire/ -- OnCusp Therapeutics (or "OnCusp"), a global biopharmaceutical company focused on translating cutting-edge research assets into innovative oncology therapeutics, announced that it has officially commenced operations both inNew York and Shanghai. OnCusp succ...

GSK Singapore and Vir Biotechnology Announce Advance Purchase Agreement with the Government of Singapore for Monoclonal Antibody Sotrovimab (VIR-7831)

2021-06-30 06:30 2323

* GSK Singapore has signed an Advance Purchase Agreement with the Government ofSingapore for sotrovimab * Sotrovimab is currently undergoing review by the Singapore Health Sciences Authority (HSA) under the Pandemic Special Access Route (PSAR) for interim authorization * Announcement follow...

I-Mab Announces Upcoming Participation at July Conference

2021-06-29 20:00 8161

SHANGHAI and GAITHERSBURG, Md., June 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conference in July. D...

4G Clinical Announces $230MM Growth Equity Investment Backed by Goldman Sachs Asset Management

2021-06-29 20:00 1424

The innovative RTSM leader grew over 100% in 2020, plans to accelerate global expansion and support critical demand for products and services WELLESLEY, Mass. and NEW YORK, June 29, 2021 /PRNewswire/ -- 4G Clinical, a cutting-edge randomization and trial supply management (RTSM) company, announc...

Seegene unveils "MOBILE STATION," for on-site routine testing at public-use facilities and communities

2021-06-29 18:00 1516

* Seegene unveils "MOBILE STATION" at the Medlab Middle East 2021 * Mobile laboratory designed for mass testing at schools, airports, or communities, delivering test results within 3h 30min with the maximum testing capacity of 7,500 a day * The biotechnology firm to sign an MOU with G42 Heal...

Yidu Tech Announces Annual Results for Fiscal Year 2021

2021-06-29 14:18 4429

BEIJING, June 29, 2021 /PRNewswire/ -- Yidu Tech Inc. ("Yidu Tech" or the "Company, together with its subsidiaries and consolidated affiliated entities, the "Group", HKEx: 2158), a healthcare big data and artificial intelligence solutions provider, announced its audited consolidated financial res...

BioVaxys Announces Non-Brokered Private Placement

2021-06-29 10:46 4468

VANCOUVER, BC, June 29, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement") consisting of up to 9,090,909 units ("Units") at a price of$0.22 per Unit for to...

CAI Announces the formation of CAI Professional Services India Private Limited.

2021-06-29 09:23 2010

INDIANAPOLIS, June 29, 2021 /PRNewswire/ -- On 25 June, 2021, CAI Professional Services India Private Limited officially opened for business. CAI is proud to now be able to serve clients in the data center, pharmaceutical, and biotechnology industries across the Indian subcontinent. Our focus on ...

Innovent Announces License Agreement with Synaffix in an ADC Technology Deal

2021-06-29 08:00 4548

SAN FRANCISCO and SUZHOU, China, June 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

First in China! Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON

2021-06-28 21:33 1475

* Novel and one-time intravitreal injection of ND4 gene therapy for the treatment of LHON potentially restored vision * Phase I/II/III clinical trial expected to enroll patients with LHON due to ND4 mutation WUHAN, China and SAN DIEGO, June 28, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd...

ILIAS Biologics Inc. demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury

2021-06-28 20:00 1289

DAEJEON, South Korea, June 28, 2021 /PRNewswire/ -- Anti-inflammatory exosomes could have a place in treating acute kidney injury (AKI) caused by ischemia repercussion injury (IRI), according to a study done by ILIAS Biologics, Inc. in collaboration withYonsei University of Seoul, South Korea. ...

BIO Asia-Taiwan 2021 to Go Ahead in 'All Online' Format

2021-06-28 07:30 1947

TAIPEI, June 28, 2021 /PRNewswire/ -- In response to ongoing restrictions in Taiwan due to the COVID-19 pandemic, BIO Asia-Taiwan 2021 will be held as scheduled fromJuly 21-25 but in an all-online format, with activities including the Conference, Exhibition, BIO's One-on-one Partnering™, Company ...

I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus

2021-06-25 20:00 16177

SHANGHAI and GAITHERSBURG, Md., June 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China N...

Happiness Biotech Announces $2.16 Million Registered Direct Offering To Strategic Investors

2021-06-25 20:00 24416

NANPING, China, June 25, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that it has entered into a securities purchase agreement with certain non-U.S. strategic investor...

Vazyme Brings COVID-19 Testing Solutions at Medlab 2021

2021-06-25 15:31 1338

DUBAI, UAE, June 25, 2021 /PRNewswire/ -- Chinese biotechnology company Nanjing Vazyme Biotech Co., Ltd (Vazyme) showcased its lineup of COVID-19 testing solutions and its point-of-care testing (POCT) in vitro diagnostic instruments at the 2021 Medlab Middle East, an industry-leading medical labo...

Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer

2021-06-25 15:06 1374

SHANGHAI, June 25, 2021 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today one study in collaboration with Ruijin Hospital, Shanghai Jiaotong ...

GenScript receives "Best Contract Development and Manufacturing Organization Award" in the Korea Bioprocessing Excellence Awards 2021

2021-06-25 10:30 17767

SINGAPORE, June 25, 2021 /PRNewswire/ -- GenScript receives the "Best Contract Development and Manufacturing Organization Award" on the Korea Bioprocessing Excellence Awards 2021 held on 24th June 2021. GenScript achieve the Best CDMO award for two years in a row.

Samsung Biologics Issues Its First Annual Sustainability Report

2021-06-25 09:01 22343

* Consolidation of the company's roadmap to creating an improved business environment * Establishment of an ESG Committee for its continued efforts for environmental performance * Showcases the company's long-term commitment to social responsibility as part of its mission to build a bett...

Bridge Biotherapeutics Integrates CDD Vault Collaborative Database Solution into Its R&D Platform to Harmonize Research and Drug Discovery Project Management

2021-06-25 05:57 2007

- Bridge has been enhancing its research and drug discovery engines by efficiently managing scientific assets on a collaborative database solution - CDD provides a secure research database platform enabling seamless collaboration between drug discovery and development teams that are in different...

Advanced Aesthetic Technologies, Inc. Announces the Treatment of the First Patient in a Pivotal Clinical Trial in China with their Algeness® VL (2.5% Agarose Gel) Filler for the Correction of Moderate to Severe Nasolabial Folds

2021-06-24 18:00 1914

This new clinical trial is being conducted through their partnership with Lanzhou Biotechnique Development Co., LTD (LanDev) and their parent company China National Biotec Group Co., LTD (CNBG) and will be used to seek marketing approval inChina BROOKLINE, Mass., June 24, 2021 /PRNewswire/ -- Ad...

1 ... 140141142143144145146 ... 150